Screener
Medpace Holdings, Inc. MEDP Cardiology — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medpace Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Medpace Holdings, Inc.’s 10-Q, filed July 23, 2026.
- Filed
- Jul 23, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001668397-26-000025
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Therapeutic Area | ||||
| Metabolic | $219,067 | $147,873 | $456,625 | $295,888 |
| Oncology | 209,372 | 188,558 | 410,611 | 359,034 |
| Other | 98,279 | 118,062 | 191,597 | 213,898 |
| Central Nervous System | 82,858 | 61,129 | 163,065 | 116,030 |
| Cardiology | 59,982 | 58,584 | 116,243 | 116,863 |
| AVAI | 37,773 | 29,105 | 75,794 | 60,168 |
| Total revenue | $707,331 | $603,311 | $1,413,935 | $1,161,881 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Medpace Holdings, Inc.'s cardiology — total revenue?
- Medpace Holdings, Inc. (MEDP) reported cardiology — total revenue of $82.86M in Q2 2026.
- How has Medpace Holdings, Inc.'s cardiology — total revenue changed year-over-year?
- Medpace Holdings, Inc.'s cardiology — total revenue increased by 35.5% year-over-year, from $61.13M to $82.86M.
- What is the long-term trend for Medpace Holdings, Inc.'s cardiology — total revenue?
- Over 4 years (2021 to 2025), Medpace Holdings, Inc.'s cardiology — total revenue has grown at a 20.3% compound annual growth rate (CAGR), from $121.55M to $254.84M.
- What does cardiology — total revenue mean?
- This metric represents the total gross revenue generated specifically from clinical research and development services provided to clients within the cardiology therapeutic area. It encompasses fees from full-service clinical trial management, bioanalytical laboratory support, and imaging services tailored to cardiovascular drug and medical device development. This figure reflects the segment's market demand and the company's ability to capture clinical trial volume in this specialized medical field.
Ask your AI about Medpace Holdings, Inc.'s cardiology — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude